The cost-effectiveness of preventing cytomegalovirus disease in AIDS patients

Interfaces

Volumn 28, Issue 3, 1998, Pages 34-51

  Paltiel, A David ^a   Freedberg, Kenneth A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0039401910     PISSN: 00922102     EISSN: None     Source Type: Journal    
DOI: 10.1287/inte.28.3.34     Document Type: Article

References (63)

1. Aboulker, J. and Swart, A. 1993, "Preliminary analysis of the Concorde trial," The Lancet, Vol. 341, No. 8849, pp. 889-890.
2. AIDS Cost and Services Utilization Survey 1994, Public use tapes #4 and #5 (PB94-189891), National Technical Information Service, Springfield, Virginia.
3. Arno, P. S.; Shenson, D.; Siegel, N. F.; Franks, P.; and Lee, P. R. 1989, "Economic and policy implications of early intervention in HIV disease," JAMA, Vol. 262, No. 11, pp. 1493-1498.
4. Balfour, H. H. 1990, "Management of cytomegalovirus disease with antiviral drugs," Reviews of Infectious Diseases, Vol. 12, Suppl. 7, pp. S849-S860.
5. Brosgart, C.; Craig, C.; Hillman, D.; Louis, T. A.; Alston, B.; Fisher, E.; and El-Sadr, W. 1996, "Final results from a randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of CMV retinal and gastrointestinal mucosal disease," Presentation Th.B.301, 11th International Conference on AIDS, Vancouver, Canada.
6. Carpenter, C. C. J.; Fischl, M. A.; Hammer, S. M.; Hirsch, M. S.; Jacobsen, D. M.; Katzenstein, D. A.; Montaner, J. S.; Richman, D. D.; Saag, M. S.; Schooley, R. T.; Thompson, M. A.; Vella, S.; Yeni, P. G.; and Volberding, P. A. 1996, "Antiretroviral therapy for HIV infection in 1996, Recommendations of an international panel," JAMA, Vol. 276, No. 2, pp. 146-154.
7. Castellano, A. R. and Nettleman, M. D. 1991, "Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia," JAMA, Vol. 266, No. 6, pp. 820-824.
8. Centers for Disease Control and Prevention 1995, "USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: A summary," Morbidity and Mortality Weekly Report, Vol. 44, No. RR-8 (July 14), pp. 1-35.
9. Drug Topics Red Book 1996, Medical Economics, Montvale, New Jersey.
10. Drummond, M. F.; Torrance, G. W.; and Mason, J. 1993, "Cost-effectiveness league tables: More harm than good?" Social Science and Medicine, Vol. 37, No. 1, pp. 33-40.
11. Enger, C.; Graham, N.; Peng, Y.; Chmiel, J. S.; Kingsley, L. A.; Detels, R.; and Munoz, A. 1996, "Survival from early, intermediate, and late stages of HIV infection," JAMA, Vol. 275, No. 17, pp. 1329-1334.
12. Fischl, M. A.; Richman, D. D.; Grieco, M. H.; and the AIDS Clinical Trials Group 1987, "The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex," New England Journal of Medicine, Vol. 317, No. 4, pp. 185-191.
13. Fischl, M. A.; Richman, D. D.; Hansen, N.; and the AZT Collaborative Working Group 1990, "The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection," Annals of Internal Medicine, Vol. 112, No. 10, pp. 727-737.
14. 3: A cost-effectiveness analysis," Journal of Acquired Immune Deficiency Syndromes, Vol. 4, No. 5, pp. 521-531.
15. Gold, M. R.; Siegel, J. E.; Russel, L. B.; and Weinstein, M. C. 1996, Cost-effectiveness in Health and Medicine, Report of the Panel on Cost-effectiveness in Health and Medicine, Oxford University Press, New York.
16. Graham, N.; Zeger, S.; Park, L.; Vermund, S.; Detels, R.; Rinaldo, C.; and Phair, J. 1992, "The effects on survival of early treatment of HIV infection," New England Journal of Medicine, Vol. 326, No. 16, pp. 1037-1042.
17. Harris, J. E. 1990, "Improved short-term survival of AIDS patients initially diagnosed with Pneumocystis carinii pneumonia, 1984 through 1987," JAMA, Vol. 263, No. 3, pp. 397-401.
18. Hellinger, F. J. 1992, "Forecasts of the costs of medical care for persons with HIV: 1992-1995," Inquiry, Vol. 29, No. 3, pp. 356-365.
19. Hellinger, F. J. 1993, "The lifetime cost of treating a person with HIV," JAMA, Vol. 270, No. 4, pp. 474-478.
20. Hellinger, F. J.; Fleishman, J. A.; and Hsia, D. C. 1994, "AIDS treatment costs during the last months of life: Evidence from the ACSUS," Health Services Research, Vol. 29, No. 5, pp. 569-581.
21. Hirsch, M. S. 1991, "Cytomegalovirus and its role in the pathogenesis of acquired immunodeficiency syndrome," Transplantation Proceedings, Vol. 23 (Suppl. 3), pp. 118-121.
22. Holtgrave, D. R. and Quails, N. L. 1995, "Threshold analysis and programs for prevention of HIV infection," Medical Decision Making, Vol. 15, No. 4, pp. 311-317.
23. Hoover, D. R.; Saah, A. J.; Bacellar, H.; Phair, J.; Detels, R.; Anderson, R.; and Kaslow, R. A. 1993, "Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study," New England Journal of Medicine, Vol. 329, No. 26, pp. 1922-1926.
24. Kaplan, R. M. and Bush, J. W. 1981, "Health-related quality of life measurement for evaluation research and policy analysis," Health Psychology, Vol. 1, No. 1, pp. 61-80.
25. Laird, N. M. and Ware, J. H. 1982, "Random effects model for longitudinal data," Biometrics, Vol. 38, No. 4, pp. 963-974.
26. Laupacis, A.; Feeny, D.; Detsky, A.; and Tugwell, P. X. 1992, "How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations," Journal of the Canadian Medical Association, Vol. 146, No. 4, pp. 473-481.
27. Lemp, G. F.; Payne, S. F.; Neal, D.; Temelso, T.; and Rutherford, G. W. 1990, "Survival trends for patients with AIDS," JAMA, Vol. 263, No. 3, pp. 402-406.
28. Mason, J.; Drummond, M. F.; and Torrance, G. W. 1993, "Some guidelines on the use of cost-effectiveness league tables," British Medical Journal, Vol. 306, No. 6877, pp. 570-572.
29. McCarthy, B.; Wong, J.; Munoz, A.; and Sonnenberg, F. 1993, "Who should be screened for HIV infection?" Archives of Internal Medicine, Vol. 153, No. 9, pp. 1107-1116.
30. McGinley, L. 1996, "States move to ration promising AIDS drugs," The Wall Street Journal, August 22, p. B1.
31. McGinnis, J. M. and Foege, W. H. 1993, "Actual causes of death in the United States," JAMA, Vol. 270, No. 18, pp. 2207-2212.
32. Merigan, T. C. 1991, "Treatment of cytomegalo-virus infection in the AIDS patient," Transplantation Proceedings, Vol. 23 (Suppl. 3), pp. 122-125.
33. Merigan, T. C. and Resta, S. 1990, "Cytomegalo-virus: Where have we been and where are we going?" Reviews of Infectious Diseases, Vol. 12 (Suppl. 7), pp. S693-S700.
34. Miller, D. K. and Homan, S. M. 1994, "Determining transition probabilities," Medical Decision Making, Vol. 14, No. 1, pp. 52-58.
35. Moore, R. D.; Hidalgo, J.; Sugland, B. W.; and Chaisson, R. E. 1991, "Zidovudine and the natural history of the acquired immunodeficiency syndrome," New England Journal of Medicine, Vol. 324, No. 20, pp. 1412-1416.
36. Moore, R. D. and Chaisson, R. E. 1995, "Survival analysis of two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS," AIDS, Vol. 9, No. 12, pp. 1337-1342.
37. Moore, R. D. and Bartlett, J. G. 1996, "Combination antiviral therapy in HIV infection: An economic perspective," PharmacoEconomics, Vol. 10, No. 2, pp. 109-113.
38. Multicenter AIDS Cohort Study (MACS) 1995, Public Data Set (Release PO4), National Technical Information Service, Springfield, Virginia.
39. National Alliance of State and Territorial AIDS Directors 1996, "The fiscal status of AIDS drug assistance programs: Findings from a January 1996 national survey of state AIDS directors," prepared for the United States Health Resources and Services Administration, Division of HIV Services (April).
40. Owens, D. K.; Nease, R. F.; and Harris, R. A. 1993, "Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings" (abstract), Medical Decision Making, Vol. 13, No. 4, p. 395.
41. Owens, D. K.; Nease, R. F.; and Harris, R. A. 1996, "Cost-effectiveness of HIV screening in acute care settings," Archives of Internal Medicine, Vol. 156, No. 4, pp. 394-404.
42. Paltiel, A. D. and Stinnett, A. A. 1996, "AIDS," In Quality of Life and Pharmacoeconomics in Clinical Trials, second edition, ed. B. Spilker, Raven Press, New York.
43. Pear, R. 1997, "Expense means many can't get drugs for AIDS," The New York Times, February 16, p. A1.
44. Pertel, P.; Hirschtick, R.; Phair, J.; Chmiel, J.; Poggensee, L.; and Murphy, R. 1992, "Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus," Journal of Acquired Immune Deficiency Syndromes, Vol. 5, No. 11, pp. 1069-1074.
45. Phair, J.; Munoz, A.; Detels, R.; Kaslow, R.; Rinaldo, C.; Saah, A.; and the Multicenter AIDS Cohort Study Group 1990, "The risk of Pneumocystis carinii pneumonia among men infected with HIV Type I. Multicenter AIDS Cohort Study Group," New England Journal of Medicine, Vol. 322, No. 3, pp. 161-165.
46. Pierce, M.; Crampton, S.; Henry, D.; Heifets, L.; LaMarca, A.; Montecalvo, M.; Wormser, G. P.; Jablonowski, H.; Jemsek, J.; Cynamon, M.; Yangco, B. G.; Notario, G.; and Craft, J. C. 1996, "A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome," New England Journal of Medicine, Vol. 335, No. 6, pp. 384-391.
47. Polis, M. A.; deSmet, M. D.; Baird, B. F.; Mellow, S.; Falloon, J.; Davey, R. T.; Kovacs, J. A.; Palestine, A. G.; Nussenblatt, R. B.; and Masur, H. 1993, "Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet)," American Journal of Medicine, Vol. 94, No. 2, pp. 175-180.
48. Robbins, G. K. and Cotton, D. J. 1997, "Cost-effectiveness of ganciclovir for prevention of CMV retinitis," Abstract 296, Session 31, Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC.
49. Rose, D. N.; Sacks, H. S.; and Lan, V. 1996, "Cost-effectiveness of oral ganciclovir to prevent cytomegalovirus disease in patients with AIDS," Presentation Th.B.303, 11th International Conference on AIDS, Vancouver, Canada.
50. Sande, M. A.; Carpenter, C. C.; Cobbs, C. G.; Holmes, K. K.; and Sanford, J. P. 1993, "Antiretroviral therapy for adult HIV-infected patients: Recommendations from a state-of-the-art conference," JAMA, Vol. 270, No. 21, pp. 2583-2589.
51. Schooley, R. T. 1990, "Cytomegalovirus in the setting of infection with human immunodeficiency virus," Reviews of Infectious Diseases, Vol. 12 (Suppl. 7), pp. S811-S819.
52. Scitovsky, A. A. and Rice, D. P. 1987, "Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991," Public Health Reports, Vol. 102, No. 1, pp. 5-17.
53. Seage, G.; Oddleifson, S.; Carr, E.; Shea, B.; Makareqicz-Robert, L.; Beuzekom, M.; and De Maria, A. 1993, "Survival with AIDS in Massachusetts 1979-1989," American Journal of Public Health, Vol. 83, No. 1, pp. 72-78.
54. Seage, G. R.; Landers, S.; Barry, M. A.; Groopman, J.; Lamb, G.; and Epstein, A. 1986, "Medical care costs of AIDS in Massachusetts," JAMA, Vol. 256, No. 22, pp. 3107-3109.
55. Spector, S. A.; Pilcher, M.; Lamy, P.; Hsia, K.; Wong, R.; Stempien, M. J.; and the Roche Cooperative Oral Ganciclovir Study Group 1996, "PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis," Presentation Th.B.302, 11th International Conference on AIDS, Vancouver, Canada.
56. Spector, S. A.; McKinley, G. F.; Lalezari, J. P.; Samo, T.; Andruczk, R.; Follansbee, S.; Sparti, P. D.; Havlir, D. V.; Simpson, G.; Buhles, W.; Wong, R.; Stempien, M.; and the Roche Cooperative Oral Ganciclovir Study Group 1996, "Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS," New England Journal of Medicine, Vol. 334, No. 23, pp. 1491-1497.
57. Tengs, T. O.; Adams, M. E.; Pliskin, J. S.; Safran, D. G.; Siegel, J. E.; Weinstein, M. C.; and Graham, J. D. 1995, "Five-hundred life-saving interventions and their cost-effectiveness," Risk Analysis, Vol. 15, No. 3, pp. 369-390.
58. Torrance, G. W. 1976, "Social preferences for health states: An empirical evaluation of three measurement techniques," Socioeconomic Planning Science, Vol. 10, No. 3, pp. 128-136.
59. Torrance, G. W.; Boyle, M. H.; and Horwood, S. P. 1982, "Application of multi-attribute utility theory to measure social preferences for health states," Operations Research, Vol. 30, No. 6, pp. 1043-1069.
60. Tsevat, J.; Solzan, J. G.; Kuntz, K. M.; Ragland, J.; Currier, J. S.; Sell, R. L.; and Weinstein, M. C. 1996, "Health values of patients infected with human immunodeficiency virus," Medical Care, Vol. 34, No. 1, pp. 44-57.
61. US Public Health Service Task Force on Antipneumocystis Prophylaxis for Patients with Human Immunodeficiency Virus Infection 1992, "Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus," Morbidity and Mortality Weekly Report, Vol. 41, No. RR-4, pp. 1-11.
62. Volberding, P. A.; Lagakos, S. W.; Koch, M. A.; Pettinelli, C.; Myers, M. W.; Booth, D. K.; Balfour, H. H.; Reichman, R. C.; Bartlett, J. A.; and Hirsch, M. S. 1990, "Zidovudine in symptomatic human immunodeficiency virus infection: A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter," New England Journal of Medicine, Vol. 322, No. 14, pp. 941-949.
63. Weinstein, M. C. 1995, "From cost-effectiveness ratios to resource allocation: Where to draw the line?" In Valuing Health Care: Costs, Benefits, and the Effectiveness of Pharmaceuticals and Other Medical Technologies, ed. F. A. Sloan, Cambridge University Press, New York.